Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

NCT00203502 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab
DRUG: Cyclophosphamide
DRUG: Docetaxel

Sponsor

University of Arkansas

Collaborators

[object Object]